WuXi AppTec, Fosun, Sinopharm and Humanwell have all invested in the oncology treatment developer, which has filed to raise up to $100m.

Ambrx Biopharma, a US-headquartered developer of antibody-based cancer treatments, has filed for a $100m initial public offering on the New York Stock Exchange that could enable a number of corporates to exit.

Founded in 2003, Ambrx is developing antibody drug conjugates (ADCs) to treat several types of cancer. Its lead drug candidate, ARX788, is an ADC being developed to treat breast and gastric cancer as well as other solid tumour conditions.

The proceeds of the IPO will be used to…